Equities

TheraCryf PLC

TCF:LSE

TheraCryf PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.21
  • Today's Change0.00 / 0.00%
  • Shares traded604.75k
  • 1 Year change-80.00%
  • Beta2.6801
Data delayed at least 20 minutes, as of Feb 06 2026 14:29 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects TheraCryf PLC share price to rise to 3.20 in the next year from the last price of 0.21.
High1,423.8%3.20
Med1,423.8%3.20
Low1,423.8%3.20

Earnings history & estimates

TheraCryf PLC reported annual 2025 losses of -0.36 per share on Jun 03, 2025.
Average growth rate+22.00%
More ▼

Revenue history & estimates

Evgen Pharma plc did not report revenues for the full year 2025. However, during the prior year the company reported revenues of 396.00k.
Average growth rate-70.14%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.